As of June 15, 2025, Minerva Neurosciences Inc (NERV) reports a Net Margin of 4.71%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Minerva Neurosciences Inc's Net Margin
Over recent years, Minerva Neurosciences Inc's Net Margin has shown limited historical data. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | 4.71% |
| 2023-12-31 | 4.71% |
This trend highlights how Minerva Neurosciences Inc manages its overall profitability and cost control over time.
Comparing Minerva Neurosciences Inc's Net Margin to Peers
To better understand Minerva Neurosciences Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Minerva Neurosciences Inc (NERV) | 4.71% |
| Liminal BioSciences Inc (LMNL) | 124.69% |
| ADMA Biologics Inc (ADMA) | 46.35% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| La Jolla Pharmaceutical Co (LJPC) | 25.96% |
| Amgen Inc (AMGN) | 12.24% |
Compared to its competitors, Minerva Neurosciences Inc's Net Margin is among the highest compared to peers, suggesting strong overall cost management and pricing power.